IRIS

Tetrachloroethylene

CASRN 127-18-4

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (38 pp, 350 K) last updated: 02/10/2012

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous 6 x 10-3 Neurotoxicity (reaction time, cognitive effects) LOAEL : 9.7
mg/kg-day
1000 Medium
Nervous 6 x 10-3 Neurotoxicity (color vision) LOAEL : 2.6
mg/kg-day
1000 Medium
Nervous x 10

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (38 pp, 350 K) last updated: 02/10/2012

System RfC (mg/m3) Basis PoD Composite UF Confidence
Nervous 4 x 10-2 Neurotoxicity (reaction time, cognitive effects) LOAEL : 56
mg/m3
1000 Medium
Nervous 4 x 10-2 Neurotoxicity (color vision) LOAEL : 15
mg/m3
1000 Medium
Nervous 4 x 10-2 Neurotoxicity (color vision) LOAEL : 15
mg/m3
1000 Medium
Nervous x 10

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (38 pp, 350 K) last updated: 02/10/2012

WOE Characterization Framework for WOE Characterization
Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Following EPA (2005a) Guidelines for Carcinogen Risk Assessment, tetrachloroethylene is "likely to be carcinogenic in humans by all routes of exposure."
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (38 pp, 350 K)

Oral Slope Factor: 2.1 x10 -3 per mg/kg-day
Drinking Water Unit Risk: 6.1 x10 -8 per µg/L
Extrapolation Method: Multistage model (with linear extrapolation from the point of departure (BMDL10), followed by route-to-route extrapolation to the oral route and interspecies extrapolation using the PBPK model of Chiu and Ginsberg (2011).
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular adenomas or carcinomas (JISA, 1993)



Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (38 pp, 350 K)

Inhalation Unit Risk: 2.6 x10 -7 per µg/m3
Extrapolation Method: Multistage model with linear extrapolation from the point of departure (BMCL10), followed by extrapolation to humans using the PBPK model of Chiu and Ginsberg (2011).
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular adenomas or carcinomas (JISA, 1993)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.